Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression data from 62 colorectal cancers

ABSTRACT: We stratified colorectal tumor samples using a new unsupervised, iterative method based on non-negative matrix factorization (NMF). The resulting five subtypes exhibited activation of specific signaling pathways, and significant differences in microsatellite status and tumor location. We could also align three CRC cell lines panels to these subtypes. mRNA from 62 colorectal tumor samples was hybridized to Affymetrix HGU133 Plus 2.0 expression arrays. Log2 gene expression values were calculated using RMA.

ORGANISM(S): Homo sapiens

SUBMITTER: Garry Beran

PROVIDER: E-GEOD-35896 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Publications

Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines.

Schlicker Andreas A Beran Garry G Chresta Christine M CM McWalter Gael G Pritchard Alison A Weston Susie S Runswick Sarah S Davenport Sara S Heathcote Kerry K Castro Denis Alferez DA Orphanides George G French Tim T Wessels Lodewyk F A LF

BMC medical genomics 20121231

<h4>Background</h4>Colorectal cancer (CRC) is a heterogeneous and biologically poorly understood disease. To tailor CRC treatment, it is essential to first model this heterogeneity by defining subtypes of patients with homogeneous biological and clinical characteristics and second match these subtypes to cell lines for which extensive pharmacological data is available, thus linking targeted therapies to patients most likely to respond to treatment.<h4>Methods</h4>We applied a new unsupervised, i ...[more]

PMID: 23272949

Similar Datasets

Gene expression data from 62 colorectal cancers

Project description:We stratified colorectal tumor samples using a new unsupervised, iterative method based on non-negative matrix factorization (NMF). The resulting five subtypes exhibited activation of specific signaling pathways, and significant differences in microsatellite status and tumor location. We could also align three CRC cell lines panels to these subtypes.

2013-01-14 | GSE35896 | GEO

DNA Methylation Identifies Genetically and Prognostically Distinct Subtypes of Myelodysplastic Syndromes

Project description:We report the identification of five subtypes of myelodysplastic syndromes (MDS) identified via unsupervised classification of DNA methylation (DNAm) profiles. Bisulfite padlock probe sequencing (BSPP) was used to measure DNAm of ~500,000 unique CpGs covering 140,749 non-overlapping regulatory regions across the genome in bone marrow DNA samples from 141 patients with MDS. Application of a non-negative matrix factorization (NMF) decomposition of DNAm profiles identified five consensus clusters described by five NMF components as the most stable grouping solution.

2019-09-30 | GSE129828 | GEO

RNA-seq access dataset for epigenomics landscape of colorectal cancer

Project description:Enhancer aberrations are beginning to emerge as a key feature of colorectal cancers, however, we have limited understanding of epigenomic patterns that distinguish tumors and underlying heterogeneity between tumors. Here, using epigenomic profiling of colorectal tumors, adenomas and normal colon tissues, we identify unique pattern of regulatory elements in colorectal cancer, which could reliably distinguish tumors from normal colon specimens. We define shared and unique enhancer elements during colorectal cancer progression using normal adjacent colon, adenomas and adenocarcinomas. We validate the functional nature of tumor-specific enhancers for important oncogenes such as ASCL2 and Fzd10. NMF clustering identified 4 epigenetic (EPIC) subtypes in colorectal cancer, which mimics consensus molecular subtypes (CMS)1, with an advantage of introducing a novel epigenetically-identifiable subtype with poor prognosis and survival. Based on this correlation, we defined and validated a combination therapeutic strategy of enhancer-blocking BETi with pathway specific inhibitor for 3 CMS subtypes. In conclusion, by comprehensive characterization of chromatin state patterns in colorectal tumors, we define epigenomic patterns during tumor evolution, heterogeneity of enhancers among patients and a combination therapy strategy for CMS-subgroups.

2021-05-22 | GSE136630 | GEO

Hi-ChIP dataset for epigenomics landscape of colorectal cancer

2021-05-22 | GSE136629 | GEO

mRNA expression data of 62 human medulloblastoma tumors

Project description:To identify molecular subtypes of medulloblastoma we have profiled a series of 62 medulloblastoma tumors. Unsupervised hierarchical cluster analysis of these data identified 5 distinct molecular subtypes. Manuscript submitted. Title: Identification of medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. Authors: Marcel Kool, Jan Koster, Jens Bunt, Nancy E. Hasselt, Arjan Lakeman, Peter van Sluis, Dirk Troost, Netteke Schouten – van Meeteren, Huib N. Caron, Alan Mršić, Bauke Ylstra, Wieslawa Grajkowska, Wolfgang Hartmann, Torsten Pietsch, David Ellison, Steven C. Clifford, Rogier Versteeg. Keywords: tumor classification

2008-09-02 | GSE10327 | GEO

mRNA expression data of 62 human medulloblastoma tumors

Project description:To identify molecular subtypes of medulloblastoma we have profiled a series of 62 medulloblastoma tumors. Unsupervised hierarchical cluster analysis of these data identified 5 distinct molecular subtypes. Manuscript submitted. Title: Identification of medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. Authors: Marcel Kool, Jan Koster, Jens Bunt, Nancy E. Hasselt, Arjan Lakeman, Peter van Sluis, Dirk Troost, Netteke Schouten â van Meeteren, Huib N. Caron, Alan MrÅ¡iÄ, Bauke Ylstra, Wieslawa Grajkowska, Wolfgang Hartmann, Torsten Pietsch, David Ellison, Steven C. Clifford, Rogier Versteeg. Keywords: tumor classification 62 human medulloblastoma samples were analzyed

2008-09-02 | E-GEOD-10327 | biostudies-arrayexpress

Subclassification of lung squamous cell carcinoma

Project description:Two subclasses of lung squamous cell carcinoma with different gene expression profiles and prognosis identified by hierarchical clustering and validated by non-negative matrix factorization . BACKGROUND: Current clinical and histopathological criteria used to define lung squamous cell carcinomas (SCCs) are insufficient to predict clinical outcome. We attempted to make a clinically-useful classification based on gene expression profiling. METHODS: We used cDNA microarrays with 40386 elements to analyze the gene expression profiles of 48 surgically resected samples of lung SCC. 9 samples of lung adenocarcinoma and 30 of normal lung were also included to give a total of 87 samples analyzed. After gene filtering, the data were subjected to hierarchical clustering and consensus clustering with the non-negative matrix factorization (NMF) approach. FINDINGS: Initial analysis by hierarchical clustering allowed division of SCCs into two distinct subclasses. An additional independent round of hierarchical clustering and consensus clustering with the NMF approach provided a validation for the classification. Kaplan-Meier analysis with the log rank test pointed to a non-significant difference in survival (p=0.071) but the likelihood of survival to 6 years was significantly different between the two groups (40.5% vs 81.8%, p=0.014, Z-test). Biological process categories characteristic for each subclass were identified statistically and up-regulation of cell-proliferation related genes was evident in the subclass with a poor prognosis. In the subclass with the better survival, genes involved in differentiated intracellular functions, such as the MAPKKK cascade, ceramide metabolism, or regulation of transcription, were up-regulated. Keywords: repeat sample

2009-04-01 | E-GEOD-2088 | biostudies-arrayexpress

Custom NanoString Gene Expression Assay for Subtype Identification in Glioblastoma

Project description:Using non-negative matrix factorization to identify glioblastoma subtypes from NanoString gene expression data

2021-06-13 | GSE177549 | GEO

Microarray gene-expression profiles of 139 pancreatic tumor,102 adjacent non-tumor tissue from patients with pancreatic ductal adenocarcinoma and 3 normal pancreas from donors.

Project description:In order to identify key pathways associated with disease aggressiveness and therapeutics resistance in the most agrressive subset of PDAC, we analyzed gene expression profiling of tumor and adjacent non-tumor tissues from PDAC cases. Non-negative matrix factorization (NMF) clustering, using gene expression profile form PDAC tumors, revealed three patient subsets. A 142-gene signature specific to the subset with the worst patient survival, predicted prognosis and stratified patients with significantly different survival. Mechanistic and functional analyses of most aggressive subset revealed a HNF1B/Clusterin Axis negatively regulate pancreatic cancer progression and potentially be useful in designing novel strategies to attenuate disease progression. Affymetrix data from from these dataset were partially earlier submited by us as GEO accession#: GSE28735 and GSE 62452. The batch effect between the different sets of data was removed using Partek Genomic Suite and this normalized data was submitted to GEO in this submission.

2022-12-01 | GSE183795 | GEO

Subclassification of lung squamous cell carcinoma

2009-04-01 | GSE2088 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data